Edwards Lifesciences Corporation

NYSE:EW

Medical - Devices

Healthcare
$105.23 +0.57%

+$0.49 today

Market cap
$60.51B
Beta
0.87
P/E (TTM)
46.2
EPS (TTM)
$1.89
52W Low $72.30High $89.60

Volume 3.92M

Average 5.02M

EW Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Edwards Lifesciences CorporationNYSE: EW

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures grows, but more slowly than its trailing trend

Q2 FY2026 capital expenditures of $66.9M (cash outflow) rose 35.7% year over year, behind the +53.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 3.1% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.

Context

  • Capital expenditures amounted to 4.3% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +35.7% toward the trailing-twelve-month pace of +53.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$66.9M+3.1% QoQ
Last fiscal yearDec 2025
-$260.2M+3.1% YoY
LTMJun 2026
-$286.7M+53.3% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.7%——
1 year+3.1%——
3-year CAGR-0.6%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(260.2M) USD
Year-over-year change
-3.1%

Capital Expenditures vs competitors

How EW compares with its peers on the latest reported figures

  • EW's LTM Jun 2026 capital expenditures of $286.7M is the 2nd largest of the 6 companies compared; the peer median is $61.9M.
  • Its year-over-year change of +53.3% is the 4th highest of 6, against a peer median of +55.3%.
  • Capital expenditures amounts to 4.4% of revenue for EW, versus a peer median of 7.2%.
EW Competitors Peer median
Capital Expenditures for EW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ISRGIntuitive Surgical, Inc.LTM Sep 2026$491.5M -28.7%+0.5%4.2%
EWEdwards Lifesciences CorporationLTM Jun 2026$286.7M +53.3%-0.6%4.4%
LIVNLivaNova PLCLTM Sep 2026$108.84M +83.8%+45.2%7.2%
PENPenumbra, Inc.LTM Jun 2026$61.9M +55.3%+48.9%4.1%
AORTArtivion, Inc.LTM Mar 2026$43.41M +287.0%+53.9%9.5%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.69M -6.5%+5.5%91.5%
Peer median (excluding EW) $61.9M+55.3%+45.2%7.2%

Competitors are the stored peer set for EW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income1.5B1.52B1.4B4.17B1.07B
Depreciation & Amortization134.8M139.6M144.9M155.2M156.6M
Deferred Income Tax(41.4M)(254.5M)(272.1M)(323.4M)(117.6M)
Stock-Based Compensation109.3M126.8M139.4M162.3M158.1M
Change in Working Capital145.3M(421.4M)(526.3M)(259.3M)154.6M
Accounts Receivables(112.4M)(84.1M)(141.2M)121.2M(23M)
Inventory19M(213.4M)(289M)(256.1M)50.7M
Accounts Payables195.2M(21.4M)146M89.5M395.1M
Other Working Capital43.5M(102.5M)(242.1M)(213.9M)(268.2M)
Other Non-Cash Items(119M)105.8M7.5M(3.36B)174.1M
Operating Cash Flow1.73B1.22B895.8M542.3M1.6B
Capital Expenditures(329.8M)(264.8M)(266.3M)(252.4M)(260.2M)
Acquisitions (Net)329.8M0(95.2M)(1.06B)0
Purchases of Investments(1.89B)(778.9M)(105.5M)(945.8M)(3.14B)
Sales of Investments529.2M1.36B715.8M857.6M2.88B
Other Investing Activities(359.3M)(63.1M)(75M)3.75B(195.7M)
Investing Cash Flow(1.72B)252.3M173.8M2.31B(712.9M)
Debt Repayment(1.8M)(200K)(300K)00
Common Stock Issued0000174.1M
Common Stock Repurchased(512.8M)(1.73B)(879.6M)(1.16B)(893.4M)
Dividends Paid00000
Other Financing Activities158.3M142.8M168.9M176.4M(237.5M)
Financing Cash Flow(356.3M)(1.58B)(711M)(983M)(956.8M)
Effect of Forex Changes13.9M19.2M16.8M38.6M(44.8M)
Net Change in Cash(332.8M)(94.8M)375.4M1.91B(119.3M)
Free Cash Flow1.4B953.4M629.5M289.9M1.34B

Edwards Lifesciences Corporation

NYSE:EW

Intrinsic Alpha fair value

Locked

Current Price

$105.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.